Top Read

Published in last 1 year |

In last 2 years |

In last 3 years |

All

Please wait a minute...


For Selected: Download Citations EndNote Ris BibTeX Toggle Thumbnails

Select

Progress in Clinical and Pharmacological Research of Angong Niuhuang Pills BAI Xue, CHEN Yafei, TANG Tian, LIU Zhejun, WANG Guoyu, TAN Tianyang Chinese Journal of Pharmacovigilance    2025, 22 (3): 349-356.   DOI: 10.19803/j.1672-8629.20240592 Abstract （1216）      PDF（pc） （1259KB）（1635）       Knowledge map    Save Objective To evaluate the clinical efficacy of Angong Niuhuang pills in the past three years and explore their pharmacological mechanisms in order to provide a reference for subsequent research. Methods By analyzing the latest data on clinical research, the therapeutic effects of Angong Niuhuang pills against such diseases as cerebral hemorrhage, cerebral infarction, craniocerebral injury, heatstroke, sepsis, viral encephalitis and pneumonia were summerized. Additionally, current pharmacological research was reviewed to analyze the mechanisms of action of Angong Niuhuang pills. Results The study found that Angong Niuhuang pills were highly effective in treating the aforementioned diseases. Pharmacological research suggested that they worked through multiple mechanisms, including anti-inflammation, antioxidation, anti-apoptosis, regulation of autophagy and mitochondrial dysfunction, inhibition of pyroptosis and ferroptosis, and regulation of metabolic products and gut microbiota. Conclusion This study has evaluated the clinical efficacy and pharmacological mechanism of Angong Niuhuang pills in the treatment of various diseases and confirmed their therapeutic effect and multi-target characteristics, providing data for subsequent research and clinical applications. Reference | Related Articles | Metrics | Comments（0）

Select

Identification of Druggable Targets for Intervertebral Disc Degeneration Based on Multi-Omics Data-Driven Mendelian Randomization and Prediction of Traditional Chinese Medicine Interventions GUO Dongqi, WANG Hao, BAI Xin, BAI Jianqi, SU Hongmei, ZHANG Jingru, GUO Xiaofei, ZHAO Xiaoqi, WANG Min, WANG Yuan, ZHANG Ping Chinese Journal of Pharmacovigilance    2025, 22 (3): 241-248.   DOI: 10.19803/j.1672-8629.20240899 Abstract （816）      PDF（pc） （2553KB）（675）       Knowledge map    Save Objective To identify druggable targets for the treatment of intervertebral disc degeneration (IDD), evaluate their safety, and to predict the traditional Chinese medicines (TCMs) that can regulate these druggable targets for IDD. Methods Data on expression quantitative trait loci of druggable genes was retrieved from the eQTLGen Consortium as exposures, while data on IDD genome-wide association study was downloaded from the GWAS Catalog to serve as outcomes for Mendelian randomization analysis intended to identify potential IDD therapeutic targets. Enrichment analyses were conducted on druggable genes related to IDD. The data on protein quantitative trait loci of druggable genes related to IDD was retrieved from the FinnGen database to validate the efficacy of these genes. A phenome-wide association study (PheWAS) via the PheWAS Portal was conducted to assess drug safety. The BATMAN-TCM 2.0 and ETCM 2.0 platforms were used to mine TCM components and analyze medication patterns. Potential lead compounds were identified through molecular docking of targets and TCM components on the CB-Dock 2 platform. Results 35 TCMs, including Corydalis yanhusuo W. T. Wang., Morinda officinalis How., and Artemisia argyi Lévl. et Vant., were found to treat IDD by regulating three druggable targets-ZP3, RRM2B, and CCL4, through their 20 active components. Gene expression MR indicated that 248 druggable genes were causally related to IDD, and enrichment analyses showed that these genes were associated with cytokine activities and cellular senescence. Protein MR validated six of these genes as druggable targets for IDD. PheWAS revealed no significant adverse effects associated with the aforementioned druggable targets. Molecular docking results showed good binding activity between the TCM components and the druggable targets, with the best binding energy of -10.2 kcal·mol-1. Conclusion Such genes as ZP3, RRM2B, and CCL4 are potential therapeutic targets for IDD with good safety profiles. TCMs like Morinda officinalis How., Corydalis yanhusuo W. T. Wang., and Artemisia argyi Lévl. et Vant. can treat IDD through these druggable targets, and their active components, such as Xanthosine, are potential compounds for new drug development. Reference | Supplementary Material | Related Articles | Metrics | Comments（0）

Select

Advancements in Treating Ischemic Stroke with Chinese Medicine Compounds Formulae LIU Wenjie, GAO Yuanyuan, BAI Xue Chinese Journal of Pharmacovigilance    2024, 21 (12): 1382-1387.   DOI: 10.19803/j.1672-8629.20240654 Abstract （811）      PDF（pc） （1427KB）（433）       Knowledge map    Save Objective To examine findings related to the applications of TCM compound formulae in the management of ischemic stroke, and to offer data for subsequent clinical and experimental investigations. Methods By searching China Knowledge Network and PubMed for articles published from the inception to October 20, 2024, TCM compound formulae were summarized and evaluated. Results Clinical investigations indicated that TCM compound formulae, including Buyang Huanwu Tang, Xinglou Chengqi Tang, and Taohong Siwu Tang, exhibited substantial therapeutic efficacy in patients with ischemic stroke. Conclusion TCM compound formulae possess considerable benefits in the management of ischemic stroke. However, investigations are comparatively limited, and there is a lack of clinical studies and large-scale trials. Multi-sample and high-quality clinical studies are lacking. Reference | Related Articles | Metrics | Comments（0）

Select

Risk Signal Mining of Adverse Events Related to Levothyroxine Sodium Tablets Based on FAERS CHEN Chongze, ZHOU Tianyu, SUN Siman, GUO Shushu, JIN Hongtao Chinese Journal of Pharmacovigilance    2024, 21 (12): 1425-1431.   DOI: 10.19803/j.1672-8629.20240036 Abstract （765）      PDF（pc） （1426KB）（539）       Knowledge map    Save Objective To analyze the adverse drug events (ADE) caused by levothyroxine sodium tablets to provide a reference for rational and safe clinical use. Methods The U. S. Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) was searched to retrieve the ADE data on the primarily suspected drug collected from the first quarter of 2015 to the second quarter of 2023. The reporting odds ratio (ROR)、proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCNPP) and multi-item gamma poisson shrinker (MGPS) methods were used to screen for effective signals of ADEs of drugs. Results A total of 271 356 ADEs related to levothyroxine tablets as the primary suspect were reported. Most of the people involved were women (198 219, 73.05%) and the patients ranged from 18 to 85 in age (62.46%). A total of 5 991 adverse events of levothyroxine sodium tablets were mined, 3 371 signals were obtained after excluding non-drug adverse event signals, and 20 organ systems were found to be involved. Fatigue (22 511 items), nausea (17 591 items), diarrhea (16 400 items), headache (15 043 items) and dyspnea (12 866 items)were the top five ADEs reported.Analysis showed that neonatal gangrene (ROR=267.57, IC025=4.66), bronchiolithiasis (ROR=187.30, IC025=267.57), homophonic association (ROR=107.03, IC025=267.57), increased trans-triiodothyronine (ROR=89.19, IC025=4.42), and decreased free thyroxine indexes (ROR=80.27, IC025=4.38）were the top five ADEs in terms of intensities of signals. Based on secondary screening, the top three PTs related to the neonatal risk signal intensity were neonatal gangrene, neonatal intestinal dilation, and neonatal thyrotoxicosis. The top three PTs regarding the stone risk signal intensity were bronchial stones, cerebral stones, and staghorn stones. A total of 146 signals that were not recorded in the instructions were found, which were mostly manifested in various examinations, gastrointestinal system diseases, infections and invasive diseases, nervous system diseases, benign and malignant tumors of unknown nature. Conclusion Levothyroxine sodium tablets can potentially cause such ADRs as calculuses, infections and secondary tumors in patients with hypothyroidism. Clinical multidisciplinary follow-up is recommended for patients taking levothyroxine sodium tablets. Reference | Related Articles | Metrics | Comments（0）

Select

Methods for Assessment of MAH Compliance with GVP LIU Ying, XIONG Shunyu, XIONG Huiyu, CAI Fei, XU Mengdan, WANG Qing, REN Wei, XU Yan Chinese Journal of Pharmacovigilance    2025, 22 (3): 282-285.   DOI: 10.19803/j.1672-8629.20240394 Abstract （747）      PDF（pc） （1207KB）（814）       Knowledge map    Save Objective To explore the methods for assessment of marketing authorization holders’ (MAHs) compliance with Good Pharmacovigilance Practice (GVP) and to design an informatized assessment tool according to applications in businesses so as to provide a reference for regulators’ efficient assessment of pharmacovigilance and for self-assessment by MAHs. Methods A system of indexes for assessment of MAHs’ compliance with GVP was developed as required by pharmacovigilance and related assessment. An informatized profiling model for MAHs’ pharmacovigilance was established via data analysis technology before the assessment methods were developed that were to be designed into assessment tools used across the province on a trial basis. Results Two hundred and ninety-nine key points of indexes for assessment and rating standards were identified, so the system and methods for assessment evaluation were established. Based on the actual operations, an informazed tool was devised and an informatized profiling model for assessment was established. Conclusion The establishment of methods for assessment of GVP compliance and informatized tools provides an innovative approach by which MAHs can improve their pharmacovigilance. Reference | Supplementary Material | Related Articles | Metrics | Comments（0）

Select

A National Pharmacovigilance Management System in a New Era YANG Xuyun, SUN Yang, TIAN Chunhua, HU Zengyao Chinese Journal of Pharmacovigilance    2025, 22 (3): 276-281.   DOI: 10.19803/j.1672-8629.20240861 Abstract （726）      PDF（pc） （1478KB）（1183）       Knowledge map    Save Objective To analyze what pharmacovigilance is about in the new era and under new circumstances and summarize related experience in order to provide a reference for the construction of a national pharmacovigilance management system. Methods Based on related laws and regulations as well as the construction of systems and mechanisms, the achievements and downsides of pharmacovigilance in China were analyzed in terms of the evolution of pharmacovigilance, and ways to improve pharmacovigilance were recommended. Results Pharmacovigilance runs through the whole life cycle of drugs and focuses on risk management, providing strong technical support for regulation of pharmaceuticals. Since the implementation of pharmacovigilance, the legal system, regulatory system, organizational system, and professionalism have been gradually established and improved, but there is also much room for improvement. Conclusion It is recommended that more efforts be made to make pharmacovigilance more scientific, standard and legalized, and that a solid bottom line for drug safety be established to promote the high-quality development of pharmacovigilance and the pharmaceutical industry. Reference | Related Articles | Metrics | Comments（0）

Select

Research Progress in Uric Acid-Lowering Drugs YAN Caiying, QIN Linying, XU Yaoqing, WANG Xinge, CHAI Nannan, CHEN Long Chinese Journal of Pharmacovigilance    2025, 22 (5): 592-595.   DOI: 10.19803/j.1672-8629.20240857 Abstract （593）      PDF（pc） （1222KB）（183）       Knowledge map    Save Objective To explore the research progress in uric acid-lowering drugs so as to provide a reference for their clinical applications. Methods By accessing the official websites of the National Medical Products Administration, China National Knowledge Infrastructure (CNKI), Wanfang Database and PubMed, information was collected on the safety of uric acid-lowering drugs, including urate transporter 1 (URAT1) inhibitors, xanthine oxidase (XO) inhibitors and exogenous uricase, which were used in the treatment of chronic gout between April 1, 2014, and September 1, 2024. In addition, the key information on 27 uric acid-lowering drugs currently under development was analyzed using the Cortellis platform. Results The adverse reactions of URAT1 inhibitors mostly involved the digestive system, manifested as liver function abnormalities. The adverse reactions caused by XO inhibitors and exogenous uric acid oxidases primarily manifested themselves as skin and mucous membrane damage and blood system damage, such as immunogenic reactions and serious cardiovascular events. The targets of action for most of the currently-developed anti-gout drugs were URAT1 inhibitors, which increased the excretion of uric acid while reducing the incidence of gout. Conclusion Although three types of drugs are usually used for the treatment of chronic gout, the potential adverse reactions remain a concern. Future research and development of anti-gout drugs should focus on dual-target or new-target drugs with unique advantages in order to offer more options for the clinical treatment of patients. Reference | Supplementary Material | Related Articles | Metrics | Comments（0）

Select

Research Progress on Models of Ischemic Stroke LIU Zhejun, TANG Tian, TAN Tianyang, BAI Xue Chinese Journal of Pharmacovigilance    2024, 21 (12): 1393-1397.   DOI: 10.19803/j.1672-8629.20240637 Abstract （554）      PDF（pc） （1476KB）（210）       Knowledge map    Save Objective To find out more about the disease mechanism of ischemic stroke, evaluate the therapeutic efficacy and predict prognosis. Methods The latest progress in clinical models, pharmacological models (including in vivo and in vitro models), and other emerging models related to ischemic stroke research was summarized. Results Clinical models were mostly used for risk prediction, prognosis assessment, and treatment decision support. Pharmacological models played a crucial role in mechanism exploration and drug screening. Emerging computer models and multi-omics models offered new perspectives for personalized treatments and precision medicine. Conclusion Despite significant advancements in ischemic stroke research, these models are still facing challenges related to clinical relevance, model integration, and translational applications. Future research should try to work on the accuracy and generalizability of models, strengthen multidisciplinary collaboration, and promote the translation of basic research into clinical practices in order to improve diagnosis, treatments, and quality of life for patients with ischemic stroke. Reference | Related Articles | Metrics | Comments（0）

Select

Chinese Journal of Pharmacovigilance    2024, 21 (12): 0-0.   Abstract （538）      PDF（pc） （443KB）（489）       Knowledge map    Save Related Articles | Metrics | Comments（0）

Select

Research Progress on Traditional Chinese Medicine Compound Formulae against Hemorrhagic Stroke LIU Zhejun, TANG Tian, TAN Tianyang, BAI Xue Chinese Journal of Pharmacovigilance    2024, 21 (12): 1405-1410.   DOI: 10.19803/j.1672-8629.20240636 Abstract （529）      PDF（pc） （1368KB）（415）       Knowledge map    Save Objective To explore the research progress in clinical efficacy and mechanisms of action of traditional Chinese medicine compound formulae in the treatment of hemorrhagic stroke in recent years, and to find out more about the potential applications of traditional Chinese medicine compound formulae. Methods Literature related to TCM compound formulae against hemorrhagic stroke that was published from inception to August 2024 was searched for in National Knowledge Infrastructure (CNKI) databases, while related research progress was summarized. Results Clinical studies showed that such TCM compound formulae as Yisui Poxue formula and decoctions for invigorating blood and removing blood stasis could do much to improve the neurological function of patients, reduce cerebral edema, facilitate recovery and improve the quality of life. Studies on the mechanisms suggested that TCM compound formulae could exert such pharmacological effects as protection of neurons, improvement of microcirculation, reduction of inflammatory response, attenuation of oxidative stress, inhibition of apoptosis, pyroptosis and ferroptosis in multi-target and multi-pathway ways. Conclusion With in-depth research, TCM compound formulae are expected to play a greater role in the comprehensive treatment of hemorrhagic stroke and provide patients with more individualized and precise treatment options, but most of the current studies are small-sample observational studies with limited evidence. More high-quality clinical studies are needed in the future to validate the efficacy of TCM compound formulae in the treatment of hemorrhagic stroke. Reference | Related Articles | Metrics | Comments（0）

Select

Research Progress in Triptolide-Induced Live Injury TANG Qianhui, ZHANG Haoran, ZHANG Luyong, JIANG Zhenzhou Chinese Journal of Pharmacovigilance    2025, 22 (2): 121-127.   DOI: 10.19803/j.1672-8629.20230658 Abstract （529）      PDF（pc） （1355KB）（581）       Knowledge map    Save Objective To summarize the research progress in the hepatotoxicity mechanism of triptolide and shed light on the mechanism of drug-induced liver injury caused by triptolide. Methods Based on literature research, the mechanism of drug induced liver injury caused by triptolide was summarized in terms of direct toxicity and indirect toxicity. Results The hepatotoxic mechanism of triptolide involved oxidative stress, mitochondrial damage, metabolic abnormalities, activation of NKT cells, imbalance between T helper cells and regulatory T cells, and increased liver sensitivity to inflammatory stimuli. Conclusion The hepatotoxicity mechanism of triptolide is complex, as there are a wide range of targets for direct toxicity. In addition, the indirect toxicity is highly concealed and complex. The elucidation of mechanisms of hepatotoxicity caused by triptolide provides a reference for enhancing the efficacy and reducing the toxicity of Tripterygium wilfordii Hook.f. and its preparations as well as for clinical safety and rational drug use. Reference | Related Articles | Metrics | Comments（0）

Select

Research Progress in Antiviral Targets and Active Ingredients of Traditional Chinese Medicine CUI Mengyao, LI Shuran, XIE Dan, YANG Xiaowei, LIU Xian, CUI Xiaolan, GENG Zihan, GUO Shanshan Chinese Journal of Pharmacovigilance    2025, 22 (5): 481-487.   DOI: 10.19803/j.1672-8629.20250099 Abstract （527）      PDF（pc） （1366KB）（184）       Knowledge map    Save Objective To elucidate the mechanisms of traditional Chinese medicine(TCM) that are characterized by multi-component, multi-target, and multi-pathway interactions, and identify bioactive components with antiviral, anti-inflammatory, and immunomodulatory properties in order to provide references for developing efficient and low-toxicity TCM formulations. Methods Modern techniques, including network pharmacology, molecular docking, high-throughput drug screening, integrative pharmacology, and structural biology, were reviewed to explore their applications in antiviral research on TCM. The binding capacity of TCM components to viral proteins and host targets, potential active ingredients in TCM formulations, and molecular pathways regulated by targets were summarized. Results TCM compounds such as flavonoids, alkaloids, glycosides, polysaccharides, and organic acids exhibited antiviral effects by directly targeting viral invasion/replication-related proteins or modulating host targets involved in immune responses and inflammatory pathways. Conclusion TCM can not only directly inhibit viral proliferation and kill viruses, but also suppress excessive immune reactions post-infection. Additionally, it enhances immunity through immunoregulation, offering indirect antiviral benefits. Reference | Supplementary Material | Related Articles | Metrics | Comments（0）

Select

Current Progress and Considerations in Updating the Safety Information in Labels of Chinese Traditional Patent Medicines ZHU Lan, SHAO Bo, ZHU Yan, DAI Jie, ZHONG Shiqi Chinese Journal of Pharmacovigilance    2025, 22 (2): 188-192.   DOI: 10.19803/j.1672-8629.20240621 Abstract （497）      PDF（pc） （1297KB）（1294）       Knowledge map    Save Objective To review Current status of updating safety information in labels of Chinese traditional patent medicines. Methods To analyze the guidelines and requirements for the updating of information on adverse reactions, contraindications, precautions and warnings information in the labels of Chinese traditional patent medicines, and to make suggestions based on working experience. Results For some historical reasons, safety information is missing from some Chinese traditional patent medicine labels and should be added to provide guidance to healthcare professionals and patients on the use of medicines. Conclusion Revision of labeling and updating of safety information is one of the risk management measures, after solving the problem of missing safety information, there is still a need for continuous monitoring of adverse reactions, post-marketing research to identify drug risks, and to control the risks by revising labels and other measures. Reference | Related Articles | Metrics | Comments（0）

Select

Applications of “Target Fishing” Technique in Pharmacological Research of Traditional Chinese Medicine CHEN Siyi, SHENG Lisong, SUN Rong Chinese Journal of Pharmacovigilance    2024, 21 (12): 1321-1328.   DOI: 10.19803/j.1672-8629.20240700 Abstract （489）      PDF（pc） （1661KB）（401）       Knowledge map    Save Objective To review the recent applications of “target fishing” technique in the fields of Traditional Chinese Medicine (TCM) in recent years in order to contribute to overcoming the bottleneck of TCM modernization caused by the complexity of TCM components and the uncertainty of target components. Methods Literature on “target fishing” techniques in the field of TCM in the past 15 years was searched. Research methods involved in the commonly used “target fishing” techniques were summarized. The strengths and weaknesses of these techniques in revealing the action or toxicity targets of TCM components were analyzed. Results “Target fishing” techniques applied in the field of TCM were mostly based on “affinity fishing”, which was often used in conjunction with liquid chromatography, mass spectrometry and other technologies for direct target research of TCM potent or toxic components on the basis of a clear mechanism of affinity fishing and toxicity. It was difficult to apply this technique to small molecules with close conformational relationships or to perform rapid and unbiased protein target identification for complex TCM systems. The interpretation of TCM theories in existing studies remained weak, and there was a lack of in-depth integration with TCM theories in subsequent validation studies or in-depth excavation. Conclusion The “target fishing” technique offers novel insights and methodologies for elucidating the molecular-level mechanisms of TCM action. This study proposes a research strategy for investigating the effects and toxicity of TCM, which should be thoroughly explored within the framework of TCM theories and substantiated from comprehensive system-level perspectives. The“target fishing” technique provides references for integrated evaluation of the “effect-toxicity” of TCM. Reference | Related Articles | Metrics | Comments（0）

Select

Key Technologies for Quality Control of Oligonucleotide Drugs LIU Bo, YUAN Yanan, WANG Yue, CHENG Shuqian, LU Zhiguo, FAN Huihong, SUN Huimin Chinese Journal of Pharmacovigilance    2025, 22 (1): 1-9.   DOI: 10.19803/j.1672-8629.20240806 Abstract （486）      PDF（pc） （2006KB）（502）       Knowledge map    Save Objective To review the basic data and quality control methods of oligonucleotide drugs in order to provide a reference for quality control of oligonucleotide drugs. Methods By searching related literature and databases at home and abroad, the methods of analysis of related substances, structural characterization, and quantification of oligonucleotides were summarized. Results There were three types of oligonucleotide drugs that had been listed: antisense oligonucleotide, small interfering RNA, and aptamer. Their domestic quality control guidelines mainly referred to foreign guidelines. Ion-pair reverse phase chromatography, ion exchange chromatography, and mass spectrometry were commonly used for quality control of oligonucleotide drugs. Other analysis techniques had their own advantages. Conclusion Significant progress has been made in quality control of oligonucleotide drugs. However, China lacks specific guidelines. Furthermore, there are several problems with the current oligonucleotide drug analysis techniques. To offer strong technical support for quality control of oligonucleotide drugs, research and the development of novel techniques are required. Reference | Related Articles | Metrics | Comments（0）

Select

Medications and Adverse Reaction in Children and Adolescents with Depressive Disorders ZHANG Longying, LOU Lifeng, YOU Qian, WEI Yubing, CAI Yan, LI Bin Chinese Journal of Pharmacovigilance    2024, 21 (12): 1419-1424.   DOI: 10.19803/j.1672-8629.20240664 Abstract （473）      PDF（pc） （1421KB）（410）       Knowledge map    Save Objective To examine the real-world clinical medications for pediatric and adolescent patients with depressive disorders, analyze the usage of drugs, and provide references for rational prescriptions. Methods The demographic characteristics, types of drugs used, treatment regimens, and adverse drug reactions among pediatric and adolescent patients with depressive disorders treated at psychological clinic of Fujian Energy General Hospital between 2019 and 2023 were analyzed. Results A total of 2 550 prescriptions for pediatric and adolescent depression patients were collected, involving 14 597 prescriptions for Western medicines and 46 583 drug entries. The majority of patients were aged 16 to 18, who far outnumbered those in groups ages 10 to 12 and 13 to 15. The average age of patients declined over time, with females outnumbering males. The five most commonly prescribed psychiatric medications were sertraline, alprazolam, quetiapine, olanzapine, and aripiprazole. The treatment approach primarily involved polypharmacy (more than 80%), with the most common regimens being antidepressant + antipsychotic (30.81%), and antidepressant + antipsychotic + sedative-hypnotic or anxiolytic (26.69%). Adverse drug reactions included gastrointestinal disorders, metabolic and nutritional disturbances, and psychiatric symptoms. Conclusion Antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs), are the mainstay of treatments for pediatric and adolescent depression in outpatient settings. Sertraline is the most commonly prescribed despite its declining usage. The typical treatment regimen involves a single antidepressant, often combined with benzodiazepine sedative-hypnotics and atypical antipsychotics. Reference | Related Articles | Metrics | Comments（0）

Select

Chinese Journal of Pharmacovigilance    2025, 22 (3): 0-0.   Abstract （473）      PDF（pc） （501KB）（179）       Knowledge map    Save Related Articles | Metrics | Comments（0）

Select

Chinese Patent Medicines for Preventing Myelosuppression in Adjuvant Treatment of Malignant Tumors: a Systematic Review and Network Meta-Analysis WANG Han, WANG Cunxuan, LYU Xuehaiyue, ZHANG Lining, SUO Yusi, GU Zhi'en, WANG Ping, JIN Xuejing Chinese Journal of Pharmacovigilance    2025, 22 (2): 169-176.   DOI: 10.19803/j.1672-8629.20240803 Abstract （433）      PDF（pc） （1515KB）（545）       Knowledge map    Save Objective To conduct a network Meta-analysis of eight Chinese patent medicines (CPMs) that are commonly used in clinical practice, have a large market share, and are relatively affordable for patients in order to assess their protective effects against myelosuppression in adjuvant radiotherapy and chemotherapy for malignant tumors. Methods CNKI, Wanfang Database, Chinese Science and Technology Journal Database, SinoMed, Cochrane Library, PubMed, and Embase were searched for related literature published from inception to April 9, 2024. Randomized controlled trials (RCTs) in which CPMs were used to prevent myelosuppression during radiotherapy in patients with solid tumors were enrolled. Two researchers independently screened the literature, retrieved the data, and evaluated the quality of the literature using the risk of bias assessment tool. Stata software was used for network Meta-analysis. Results The number of RCTs included was 48 involving a total of 4 204 patients and eight CPMs, namely, Diyu Shengbai tablets, Qijiao Shengbai capsules, compound E Jiao Jiang, compound Zaofan pills, Zhenqi Fuzheng granules (capsule and punch), Shengxuebao mixture, Shenqi Shiyiwei granules and Shiyiwei Shenqi capsules. The results showed that Diyu Shengbai tablets, Qijiao Shengbai capsules, and Fufang Zaofan pills could reduce the incidence of myelosuppression while compound E Jiao Jiang, Diyu Shengbai tablets, and Zhenqi Fuzheng granules could reduce the incidence of leukopenia. Conclusion CPMs of the “buqi shengxue” category can reduce the incidence of myelosuppression and leukopenia during adjuvant treatment of malignant tumors, among which Shenqi Shiyiwei granules, Zhenqi Fuzheng granules (capsule and punch), and compound E Jiao Jiang have the better protective effect against myelosuppression. Reference | Related Articles | Metrics | Comments（0）

Select

Chinese Journal of Pharmacovigilance    2025, 22 (2): 0-0.   Abstract （426）      PDF（pc） （480KB）（479）       Knowledge map    Save Related Articles | Metrics | Comments（0）

Select

Research Progress in the Treatment of Advanced Non-Small Cell Lung Cancer with Aumonertinib YANG Shengxi, XU Juntong, TU Wenlian Chinese Journal of Pharmacovigilance    2025, 22 (2): 235-240.   DOI: 10.19803/j.1672-8629.20240491 Abstract （410）      PDF（pc） （1290KB）（485）       Knowledge map    Save Objective To investigate the clinical efficacy of aumonertinib as the third representative epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKIs) in patients with advanced epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC). Methods The clinical efficacy of aumonertinib against advanced NSCLC with classical EGFR mutation, advanced NSCLC with T790M drug-resistant mutation, and advanced NSCLC with rare EGFR mutation as well as the research progress in combined treatment with aumonertinib to delay the occurrence of drug resistance were reviewed. Results In real-world studies, aumonertinib extended the median progression-free survival (mPFS) to 20 months in NSCLC patients with classical EGFR mutations and to 15 months in NSCLC patients with T790M resistance mutations. Aumonertinib also showed good efficacy in NSCLC patients with rare mutations. The combination therapy with aumonertinib could effectively slow down the occurrence of drug resistance. Conclusion Aumonertinib has a marked clinical effect on patients with advanced NSCLC, which can effectively improve the survival time and prognosis of patients. Reference | Related Articles | Metrics | Comments（0）